Brain deposition of transactive response DNA-binding protein 43 (TDP-43) is a feature of neurodegenerative syndromes. We evaluated TDP-43 plasma concentrations in 1058 participants in the Cardiovascular Health Study (CHS), a population-based longitudinal cohort. The cohort was 38% male, 11% Black, had a mean age 75 years, and 261 people developed dementia over a mean of 5.5 years of follow up. Median TDP-43 levels were 211.0 pg/mL (IQR: 134.0–341.0 pg/mL). TDP-43 levels were not associated with cross-sectional or longitudinal change in cognitive scores, with plasma AD biomarkers, with brain MRI volumes, with incident dementia, or with demographic characteristics.
SahooABejaninAMurrayME, et al.TDP-43 and Alzheimer's disease pathologic subtype in non-amnestic Alzheimer's disease dementia. J Alzheimers Dis2018; 64: 1227–1233.
2.
PraterKELatimerCSJayadevS. Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes. Glia2022; 70: 239–255.
3.
JosephsKAMurrayMEWhitwellJL, et al.Staging TDP-43 pathology in Alzheimer's disease. Acta Neuropathol2014; 127: 441–450.
4.
JoMLeeSJeonY-M, et al.The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med2020; 52: 1652–1662.
5.
MercadoPAAyalaYMRomanoM, et al.Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res2005; 33: 6000–6010.
6.
BudiniMBurattiEMorselliE, et al.Autophagy and its impact on neurodegenerative diseases: new roles for TDP-43 and C9orf72. Front Mol Neurosci2017; 10: 170.
7.
NagSYuLBoylePA, et al.TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease. Acta Neuropathol Commun2018; 6: 33.
8.
Amador-OrtizCLinWLAhmedZ, et al.TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol2007; 61: 435–445.
9.
UryuKNakashima-YasudaHFormanMS, et al.Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol2008; 67: 555–564.
10.
NelsonPTBrayneCFlanaganME, et al.Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol2022; 144: 27–44.
11.
FouldsPMcAuleyEGibbonsL, et al.TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol2008; 116: 141–146.
12.
VerstraeteEKuiperijHBvan BlitterswijkMM, et al.TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler2012; 13: 446–451.
13.
KojimaYKasaiTNotoYI, et al.Amyotrophic lateral sclerosis: correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics. PLoS One2021; 16: e0260323.
14.
KasaiTKojimaYOhmichiT, et al.Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. Ann Clin Transl Neurol2019; 6: 2489–2502.
15.
FenebergESteinackerPLehnertS, et al.Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener2014; 15: 351–356.
16.
ChatterjeeMÖzdemirSFritzC, et al.Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. Nat Med2024; 30: 1771–1783.
17.
FriedLPBorhaniNOEnrightP, et al.The cardiovascular health study: design and rationale. Ann Epidemiol1991; 1: 263–276.
18.
BarlowWEIchikawaLRosnerD, et al.Analysis of case-cohort designs. J Clin Epidemiol1999; 52: 1165–1172.
19.
AustinTRMcHughCPBrodyJA, et al.Proteomics and population biology in the cardiovascular health study (CHS): design of a study with mentored access and active data sharing. Eur J Epidemiol2022; 37: 755–765.
20.
LongstrethWTJrDulbergCManolioTA, et al.Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the cardiovascular health study. Stroke2002; 33: 2376–2382.
21.
LongstrethWTJrArnoldAMBeauchampNJJr., et al.Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the cardiovascular health study. Stroke2005; 36: 56–61.
22.
LongstrethWTJrBernickCManolioTA, et al.Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the cardiovascular health study. Arch Neurol1998; 55: 1217–1225.
23.
LopezOLKullerLHFitzpatrickA, et al.Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology2003; 22: 1–12.
24.
StevensLACoreshJSchmidCH, et al.Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis2008; 51: 395–406.
25.
LongstrethWTBernickCFitzpatrickA, et al.Frequency and predictors of stroke death in 5,888 participants in the cardiovascular health study. Neurology2001; 56: 368–375.
26.
RajiCALopezOLKullerLH, et al.White matter lesions and brain gray matter volume in cognitively normal elders. Neurobiol Aging2012; 33: 834.e7–834.e16.
27.
FischlB. Freesurfer. Neuroimage2012; 62: 774–781.
28.
McDowellIKristjanssonBHillGB, et al.Community screening for dementia: the mini mental state exam (MMSE) and modified mini-mental state exam (3MS) compared. J Clin Epidemiol1997; 50: 377–383.
29.
ArnoldAMNewmanABDermondN, et al.Using telephone and informant assessments to estimate missing modified mini-mental state exam scores and rates of cognitive decline. The cardiovascular health study. Neuroepidemiology2009; 33: 55–65.
30.
OddenMCKohWJHArnoldAM, et al.Trajectories of nonagenarian health: sex, age, and period effects. Am J Epidemiol2019; 188: 382–388.
31.
FitzpatrickALKullerLHIvesDG, et al.Incidence and prevalence of dementia in the cardiovascular health study. J Am Geriatr Soc2004; 52: 195–204.
32.
KullerLHLopezOLJagustWJ, et al.Determinants of vascular dementia in the cardiovascular health cognition study. Neurology2005; 64: 1548–1552.
33.
PrenticeRL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika1986; 73: 1–11.
34.
NelsonPTDicksonDWTrojanowskiJQ, et al.Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain2019; 142: 1503–1527.
35.
LopezOLKoflerJChangY, et al.Hippocampal sclerosis, TDP-43, and the duration of the symptoms of dementia of AD patients. Ann Clin Transl Neurol2020; 7: 1546–1556.
36.
ChiangCHGrauffelCWuLS, et al.Structural analysis of disease-related TDP-43 D169G mutation: linking enhanced stability and caspase cleavage efficiency to protein accumulation. Sci Rep2016; 6: 21581.
37.
HergesheimerRCChamiAAde AssisDR, et al.The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?Brain2019; 142: 1176–1194.
38.
FouldsPGDavidsonYMishraM, et al.Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol2009; 118: 647–658.
39.
NascimentoCSuemotoCKRodriguezRD, et al.Higher prevalence of TDP-43 proteinopathy in cognitively normal Asians: a clinicopathological study on a multiethnic sample. Brain Pathol2016; 26: 177–185.
40.
HuieEZEscuderoASaitoN, et al.TDP-43 pathology in the setting of intermediate and high Alzheimer's disease neuropathologic changes: a preliminary evaluation across ethnoracial groups. J Alzheimers Dis2023; 91: 1291–1301.
41.
NagSBarnesLLYuL, et al.Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents. Neurology2020; 95: e2056–e2064.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
